SynthesisMycoses2022
Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review.
Synthesis in Mycoses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Pooled it
- Pooled it
- Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization-Florida, 2019-2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Host-Candida auris interactions in the skin.PLoS pathogens · 2026Review
- Circulation of fluconazole-resistant Candida auris in Peru confirmed by genomic analysis.Memorias do Instituto Oswaldo Cruz · 2026Article
- Analysis of the clinical characteristics and nursing strategies for 11 cases of Candida auris bloodstream infection.BMC infectious diseases · 2025Article
- Article
- Patterns and Predictors ofJournal of fungi (Basel, Switzerland) · 2025Article
- Risk Factors forInfection and drug resistance · 2025Article
- Article
- Review
- Review and Current Perspectives on DNA Topoisomerase I and II Enzymes of Fungi as Study Models for the Development of New Antifungal Drugs.Journal of fungi (Basel, Switzerland) · 2024Review
- Sunflower Oil and Cholesterol Nanoemulsion: A Novel Carrier for Micafungin to Combat Multi-ResistantPathogens (Basel, Switzerland) · 2024Article
- Review
- Enhancing ICUFrontiers in cellular and infection microbiology · 2024Article
- Preparation, Physicochemical Characterization, and Stability Study ofPharmaceutical nanotechnology · 2024Article
- Act Now: The Global Threat of Candida Auris and the Urgent Need for Effective Countermeasures.Journal of community hospital internal medicine perspectives · 2024Article
- The Gordian Knot ofPathogens (Basel, Switzerland) · 2023Review
- Description ofHealthcare (Basel, Switzerland) · 2023Article
- An Autochthonous SusceptibleJournal of fungi (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida auris is an emerging multidrug-resistant pathogen in intensive care settings (ICU). During the coronavirus disease 19 (COVID-19) pandemic, ICU admissions were overwhelmed, possibly contributing to the C. auris outbreak in COVID-19 patients.
objectivesThe present systematic review addresses the prevalence, underlying diseases, iatrogenic risk factors, treatment and outcome of C. auris infections in COVID-19 patients.
methodsMEDLINE, Scopus, Embase, Web of Science and LitCovid databases were systematically searched with appropriate keywords from 1 January 2020 to 31 December 2021.
resultsA total of 97 cases of C. auris were identified in COVID-19 patients. The pooled prevalence of C. auris infections (encompassing candidemia and non-candidemia cases) in COVID-19 patients was 14%. The major underlying diseases were diabetes mellitus (42.7%), hypertension (32.9%) and obesity (14.6%), followed by the iatrogenic risk factors such as a central venous catheter (76.8%%), intensive care unit (ICU) stay (75.6%) and broad-spectrum antibiotic usage (74.3%). There were no significant differences in underlying disease and iatrogenic risk factors among C. auris non-candidemia/colonisation and C. auris candidemia cases. The mortality rate of the total cohort is 44.4%, whereas, in C. auris candidemia patients, the mortality was 64.7%.
conclusionThis study shows that the prevalence of C. auris infections remains unchanged in the COVID-19 pandemic. Hospital-acquired risk factors may contribute to the clinical illness. Proper infection control practices and hospital surveillance may stop future hospital outbreaks during the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.